Horizon Pharma Bids $3 Billion For Depomed #mcneil #pharma

Posted On Dec 8 2017 by

#horizon pharma # Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management. Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer. The Irish manufacturer of drugs …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #forest #pharma

Posted On Dec 7 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #mba

Posted On Nov 30 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Horizon Pharma Bids $3 Billion For Depomed #abbott #pharma

Posted On Nov 29 2017 by

#horizon pharma # Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management. Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer. The Irish manufacturer of drugs …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #biotechnology #industry

Posted On Nov 29 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Teva Buys Drug Rival, Barr, for $ Billion #pharma #logo

Posted On Nov 23 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #industries

Posted On Oct 4 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Teva Buys Drug Rival, Barr, for $ Billion #pharmajob

Posted On Sep 30 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #perdue #pharma

Posted On Sep 25 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #pharmaceutical #advertising

Posted On Aug 13 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …